Bruton's tyrosine kinase inhibitor

Patent metadata

Field	Value
Publication number	US-9814709-B2
Application number	US-201515320120-A
Country	US
Kind code	B2
Filing date	Jan 27, 2015
Priority date	Jun 20, 2014
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.

First claim

The invention claimed is:

1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate, ester, acid, or prodrug thereof:

wherein, Ar is selected from the group consisting of

Z is selected from the group consisting of

R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, and C 1-6 haloalkyl;
R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 heteroalkyl, C 1-6 haloheteroalkyl, C 3-6 cycloalkyl, C 3-6 halocycloalkyl, C 2-6 heterocycloalkyl, C 2-6 haloheterocycloalkyl, cyano and ester groups;
R 5 is hydrogen;
R 6 is selected from the group consisting of hydrogen, halogen, diazo and C 1-6 alkyl.

2. The compound of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, and C 1-4 haloalkyl.

3. The compound of claim 1 , wherein R 2 is hydrogen.

4. The compound of claim 1 , wherein R 3 and R 4 are independently selected from the group consisting of hydrogen, cyano, ester, C 1-4 haloalkyl, and C 1-4 heteroalkyl.

5. The compound of claim 1 , wherein the compound is selected from the following:

6. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, ester, acid, or prodrug thereof, and a pharmaceutically acceptable carrier or excipient, and optionally other therapeutic agents.

7. A method for the inhibition of the activity of Bruton's tyrosine kinase, comprising administering the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, ester, acid, or prodrug thereof, or a pharmaceutical composition comprising the compound of claim 1 .

8. A method for the treatment or amelioration of a disease, disorder, or condition in a subject, which is modulated or otherwise affected by tyrosine kinase activity, or in which tyrosine kinase activity is implicated, comprising administering to the subject the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, ester, acid, or prodrug thereof, or a pharmaceutical composition comprising the compound of claim 1 .

9. The method of claim 8 , wherein the disease, disorder, or condition is cancer and/or an autoimmune disease.

10. The method of claim 9 , wherein the cancer is selected from the group consisting of initiation or progression of solid tumor, B-cell lymphoma, sarcoma, lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, lymphomatoid granulomatosis, breast ductal carcinoma, lobular carcinoma, adenocarcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, or B-cell proliferative disease, or the combination thereof.

11. The method of claim 10 , wherein the cancer is selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, or B-cell proliferative disease, or the combination thereof.

12. The method of claim 11 , wherein the B-cell proliferative disease is selected from the group consisting of chronic lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia, or the combination thereof.

13. The method of claim 9 , wherein the autoimmune disease is selected from the group consisting of arthritis, rheumatic arthritis, osteoarthritis, lupus, rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease, Sjögren's syndrome, multiple sclerosis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylosis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia, scleroderma, or vulvodynia, or the combination thereof.

Assignees

• Hefei Inst Physical Sci Cas
• Anhui New Star Pharmaceutical Dev Co Ltd
• Anhui New Star Pharmaceutical Dev Co Ltd

Inventors

• Liu Qingsong
• Liu Jing
• Chen Yongfei
• Wu Hong
• Wang Aoli
• Wang Beilei
• Hu Chen
• Wang Wenchao
• Chen Cheng

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title